International Journal of Rheumatology

International Journal of Rheumatology / 2019 / Article

Erratum | Open Access

Volume 2019 |Article ID 8635073 | https://doi.org/10.1155/2019/8635073

Chris Walker, "Erratum to “Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac”", International Journal of Rheumatology, vol. 2019, Article ID 8635073, 1 page, 2019. https://doi.org/10.1155/2019/8635073

Erratum to “Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac”

Received03 Feb 2019
Accepted06 Feb 2019
Published02 Jun 2019

In the article titled “Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac” [1], there was an error in reference where it should be replaced with the article titled “A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis” [2].

References

  1. C. Walker, “Are all oral COX-2 selective inhibitors the same? a consideration of celecoxib, etoricoxib, and diclofenac,” International Journal of Rheumatology, vol. 2018, Article ID 1302835, 12 pages, 2018. View at: Publisher Site | Google Scholar
  2. A. K. Matsumoto, A. Melian, D. R. Mandel et al., “A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis,” Journal of Rheumatology, vol. 29, no. 8, pp. 1623–1630, 2002. View at: Google Scholar

Copyright © 2019 Chris Walker. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views839
Downloads298
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.